Lyra Therapeutics (LYRA) AI Stock Analysis

• Market Cap: $870.23K
• Dividend Yield: N/A
• Average Volume (3M): 98.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.89
• Revenue Growth: -59.21%
• EPS Growth: 68.97%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 1,774,882
• 10 Day Avg. Volume: 160,358
• 30 Day Avg. Volume: 98,915
• PEG Ratio: -0.53
• Price to Book (P/B): 57.96
• Price to Sales (P/S): 438.05
• P/FCF Ratio: -9.29
• Enterprise Value/Market Cap: 11.61
• Enterprise Value/Revenue: 16.84
• Enterprise Value/Gross Profit: 33.68
• Enterprise Value/Ebitda: -0.33
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.99
• Revenue Forecast (FY): $2.70M

• Rating: 41 Neutral
• Price Target: $1.50 ▼(-24.24% Downside)
• Action: Upgraded Date: 01/29/26
• Date: Action: Upgraded 01/29/26

The score is driven primarily by weak financial performance (minimal revenue, large losses, heavy cash burn, and negative equity) and bearish technicals (price well below key moving averages with negative MACD). A highly negative corporate event (program halt, near-total workforce reduction, leadership changes, and strategic-alternatives process) adds material risk, while valuation metrics offer limited support due to ongoing losses and no dividend.

Positive Factors

Platform technology (XTreo)

A proprietary local extended‑release delivery platform drives durable differentiation in ENT indications by improving local exposure and reducing systemic side effects. This structural advantage supports potential higher efficacy, repeatable product launches, and licensing or partnership value beyond any single asset.

Negative Factors

Halt of lead program

Suspending development of the lead asset removes the company's primary growth engine and eliminates the internal path to commercialization. This structural step reduces pipeline momentum, erodes R&D capability, and shifts future value realization toward external transactions rather than organic product launches.

Lyra Therapeutics Business Overview & Revenue Model

Company Description

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medic...

Read more

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medic...

How the Company Makes Money

Lyra Therapeutics generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which may involve licensing deals that provide upfront payments, milestone payments based on development progress, and roya...

Read more

Lyra Therapeutics generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which may involve licensing deals that provide upfront payments, milestone payments based on development progress, and roya...

Lyra Therapeutics Financial Statement Overview

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	600.00K	1.53M	1.56M	1.36M	285.00K	0.00
Gross Profit	300.00K	1.53M	1.56M	1.36M	-29.41M	-12.52M
EBITDA	-30.56M	-60.26M	-65.25M	-53.92M	-42.61M	-22.11M
Net Income	-32.95M	-93.44M	-62.68M	-55.28M	-43.51M	-22.13M
Balance Sheet
Total Assets	43.71M	66.35M	142.60M	109.97M	54.87M	80.83M
Cash, Cash Equivalents and Short-Term Investments	22.05M	40.58M	102.75M	97.89M	45.75M	74.59M
Total Debt	31.38M	34.38M	26.88M	4.18M	1.45M	2.44M
Total Liabilities	48.04M	54.75M	53.18M	29.21M	20.55M	6.34M
Stockholders Equity	-4.33M	11.59M	89.42M	80.75M	34.32M	74.49M
Cash Flow
Free Cash Flow	-34.11M	-72.35M	-64.35M	-43.55M	-29.20M	-22.92M
Operating Cash Flow	-34.15M	-70.01M	-63.30M	-43.38M	-25.82M	-21.14M
Investing Cash Flow	28.13M	80.31M	-12.58M	-65.01M	-3.38M	-1.77M
Financing Cash Flow	4.27M	8.53M	65.69M	96.26M	359.00K	87.70M

Lyra Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.98
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYRA, the sentiment is Negative. The current price of 1.98 is above the 20-day moving average (MA) of 0.94, above the 50-day MA of 1.42, and below the 200-day MA of 5.32, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 27.14 is Positive, neither overbought nor oversold. The STOCH value of 14.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LYRA.

Lyra Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LYRA	41 Neutral	$870.23K	-0.48	-1032.82%	―	-59.21%	68.97%
XTLB	―	$6.68M	-5.84	―	―	―	65.45%
MBIO	50 Neutral	$5.80M	-25.06	-418.83%	―	―	98.58%
RNAZ	49 Neutral	$7.83M	-0.46	-684.86%	―	―	96.75%
BOLT	41 Neutral	$8.65M	-0.31	-97.58%	―	-46.88%	34.83%
SLXN	41 Neutral	$4.73M	-0.21	-529.06%	―	―	91.47%

Lyra Therapeutics Corporate Events